This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy. The study did not meet the primary end point of OS. Longer rPFS and a higher PSA50 rate with orteronel-prednisone indicate antitumor activity.

READ FULL ARTICLE Curated publisher From Mdlinx